Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib Plus Chemotherapy vs Osimertinib Monotherapy in EGFRm NSCLC With ctDNA Persistence
NCT04769388Phase 2Completed
- Sponsor
- Beijing Cancer Prevention & Treatment Society
- Start
- Dec 2021
- Primary completion
- Jan 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Beijing Cancer Prevention & Treatment Society. Primary endpoint: Progression-Free Survival. Started Dec 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04769388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04769388.